Featured Clinical Trials

Val Nassiri
Email: [email protected] 
Phone: +1 646-703-1945

About this trial:

This Phase 1 study evaluates the safety, tolerability, preliminary efficacy, and dosimetry of a radiopharmaceutical drug candidate (a Radio-DARPin) that targets DLL3 on the surface of cancer cells to deliver a radioactive 212Pb payload. 

Eligible patients must be ≥18 years old and have either:

1. Extensive-stage or limited-stage SCLC with progression or recurrence after at least two prior lines of systemic therapy, OR
2. Large-cell lung cancer with progression or recurrence after at least one prior line of systemic therapy

Email: [email protected]

About this trial:

The goal of this trial is to learn about the safety of a trial drug called BNT327 and whether it works compared to existing treatment for people with advanced non-small cell lung cancer who have not had treatment yet. BNT327 is designed to block two mechanisms the cancer uses to evade the immune system’s natural defense, thereby aiming to enhance anti-tumor responses. More than 1000 patients have been treated with BNT327 in clinical trials to date. Multiple clinical trials are currently ongoing evaluating BNT327 either on its own or in combination with other treatments.

The trial will be conducted in two portions:

The earlier portion of the trial will evaluate safety and efficacy of different doses of BNT327 in combination with chemotherapy and alone and how well it works compared to existing treatment.

The later portion of the trial will evaluate the safety and effectiveness of BNT327 in combination with chemotherapy and alone, compared to pembrolizumab (a lung cancer treatment that’s already approved in many countries).

Participant inclusion criteria:

1. You are 18 years or older.
2. You have been diagnosed with advanced non-small cell lung cancer that has not been treated yet.
3. You have at least one tumor that can be measured by doctors.

Participant exclusion criteria:

1. You have already received treatment for your lung cancer.
2. You have other health conditions that could make it unsafe to take part (the trial team will review this with you).
3. You are pregnant or breastfeeding.
    

Email: [email protected]

About this trial:

In this trial, researchers are evaluating the safety of BNT327 and whether it works when combined with standard chemotherapy drugs (etoposide and carboplatin). They will compare it to another treatment called atezolizumab when also combined with the same chemotherapy drugs. Atezolizumab is an immunotherapy already approved in multiple countries. The goal is to determine which one works better for patients who have not been treated before for extensive-stage small cell lung cancer.

Participant inclusion criteria: 

1. You are 18 years or older.
2. You have been diagnosed with extensive-stage small cell lung cancer.
3. Your small-cell lung cancer is advanced or it has been at least 6 months since your last treatment for limited-stage disease.
4. You have at least one tumor that can be seen on a scan.

Participant exclusion criteria:

1. You are pregnant or breastfeeding.
2. You have already started treatment for your small cell lung cancer within the past 6 months.
3. You have a serious heart condition or uncontrolled illness that could affect your safety during the trial.
4. You have active infections (like tuberculosis or hepatitis) or serious immune system conditions.
    

Phone Number: 857-357-7000 
Email: [email protected]

About this trial:

This is a multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC). Patients will be randomized in a 1:1 ratio (approximately 225 in each arm) to receive either neladalkib (NVL-655) or alectinib. 

Who can participate:

Patients must have documented ALK rearrangement via testing of tissue or blood and presence of measurable disease by RECIST 1.1. Patients cannot have a known oncogenic driver alteration other than ALK or the presence of brain metastases associated with progressive neurological symptoms or requiring increasing dose of corticosteroids to control CNS disease. 

Phone Number: 855.907.3286
Email: [email protected]

About this trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy given with chemotherapy compared to standard of care immunotherapy given with chemotherapy in people with extensive-stage small cell lung cancer who have not received prior treatment for advanced disease.

Participants who qualify will be assigned to receive one of the two treatment approaches.

The purpose of the study is to compare the safety and effectiveness of the investigational treatment and to help determine whether it may offer benefit for patients in the future.

Who can participate:

The study is open to patients with extensive-stage small cell lung cancer who have not received prior systemic treatment for advanced disease and are able to meet the study requirements.
 

Phone Number: 855.907.3286
Email: [email protected]

About the trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy combination given with chemotherapy compared to a standard immunotherapy plus chemotherapy in people with advanced or recurrent non small cell lung cancer (NSCLC) who have not received prior treatment for advanced disease. 

Participants who qualify will be assigned to receive one of the two options.

The purpose of the study is to compare the safety and effectiveness of these approaches and to help determine whether the investigational treatments may offer benefit for patients in the future.